AMAG Pharmaceuticals

Akebia Therapeutics Announces Appointment of Nicholas Grund as Chief Commercial Officer

Retrieved on: 
Tuesday, January 9, 2024
Kidney disease, Genomics, Dialysis, Patient, AKBA, Sanofi, AMAG Pharmaceuticals, Nursing

CAMBRIDGE, Mass., Jan. 9, 2024 /PRNewswire/ -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced the appointment of Nicholas Grund as Chief Commercial Officer.

Key Points: 
  • CAMBRIDGE, Mass., Jan. 9, 2024 /PRNewswire/ -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced the appointment of Nicholas Grund as Chief Commercial Officer.
  • Mr. Grund is a seasoned pharmaceutical executive with significant operational, commercial and strategic leadership experience across renal and specialty markets.
  • "Nik is a profoundly knowledgeable executive with an impressive track record of leading commercial initiatives within the renal market," said John P. Butler, Chief Executive Officer of Akebia.
  • He was also Chief Commercial Officer of AMAG Pharmaceuticals where he managed commercial activities across four business units.

Vera Therapeutics Announces Appointment of Industry Veterans Robert Brenner, M.D. as Chief Medical Officer and William D. Turner as Chief Development Officer

Retrieved on: 
Monday, January 8, 2024
AMAG Pharmaceuticals, Vaccine, Hospital, Immunoglobulin A, Nephrology, Amgen, Biotechnology, AstraZeneca, Drug development, Allergy, IgA nephropathy, MAA, MedImmune, Darbepoetin alfa, Johns Hopkins University, NDA, Medical microbiology, California State University, Therapy, GSK, Stanford University Medical Center, Peanut allergy, Regulatory affairs, Kidney, SVP, Patient, Hematology, Iron(II,III) oxide, Pharmaceutical industry

The company has appointed Robert M. Brenner, M.D., as Chief Medical Officer to succeed Dr. Celia Lin, M.D.

Key Points: 
  • The company has appointed Robert M. Brenner, M.D., as Chief Medical Officer to succeed Dr. Celia Lin, M.D.
  • ; and William D. Turner as Chief Development Officer, effective immediately.
  • Rob and Bill each have successfully guided multiple therapies through late clinical development, regulatory approval and commercial launch.
  • This is a key moment for Vera as we continue to advance the strategy for our late-stage clinical program,” said Marshall Fordyce, M.D., Chief Executive Officer of Vera Therapeutics.

XORTX Welcomes New Member to the Board of Directors

Retrieved on: 
Tuesday, January 2, 2024
AMAG Pharmaceuticals, Bryant University, Nephrology, Johnson & Johnson, Kidney disease, Rensselaer Polytechnic Institute, MBA, Therapy, CSL Vifor, Knowledge, Laboratory, Abbott Laboratories, Pharmaceutical industry

CALGARY, Alberta, Jan. 02, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, welcomes Mr. Patrick Treanor to the Board of Directors and announces the resignation of Ian Klassen, both effective December 31, 2023.

Key Points: 
  • CALGARY, Alberta, Jan. 02, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, welcomes Mr. Patrick Treanor to the Board of Directors and announces the resignation of Ian Klassen, both effective December 31, 2023.
  • He previously served as President, US for Vifor Pharma, an international pharmaceutical company focused on nephrology.
  • Mr. Treanor currently serves on the board of directors of KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors.
  • Anthony Giovinazzo, Chair of XORTX, stated, “We are very pleased to have Patrick Treanor agree to join the XORTX board.

Landsdowne Labs Names Bryan Laulicht CEO

Retrieved on: 
Tuesday, June 13, 2023
Batteries, Parenting, Children, Family, Consumer Electronics, Technology, Consumer, Other Technology, Columbia University, Partnership, Therapy, Lansdowne, NSF, Medicine, MIT, Doctor of Philosophy, Harvard University, Johns Hopkins University, Running, AMAG, Lauren Fensterstock, Laboratory, Patient, Risk, Mining, Outline of health sciences, Hospital, AMAG Pharmaceuticals, Death, BA, Safety, Management, Electric battery, Pharmaceutical industry, Investment, Brigham, Biophysics

Laulicht, who will assume his new position on July 3, 2023, was instrumental in developing Landsdowne’s technology-- first as a post-doctoral associate in the laboratories of Robert Langer, of MIT, and of Jeffrey Karp, PhD, at Harvard, and, later, at Landsdowne.

Key Points: 
  • The Directors of Landsdowne Labs, LLC, are pleased to announce the appointment of Bryan Laulicht to Chief Executive Officer.
  • “Bryan Laulicht is an ideal person to lead Landsdowne toward its commercial launch,” said Doug Roth, a Landsdowne Board member who is Managing Director of Investments at Connecticut Innovations (CI), a quasi-state agency that is a lead investor in the company.
  • Fensterstock, who will remain involved with Landsdowne Labs in advisory and other Board capacities, will join a major “deep tech” venture fund that is based in Boston.
  • Landsdowne Labs is commercializing this groundbreaking technology for global companies seeking a turnkey, low-cost solution to the growing button battery health crisis.

Landos Biopharma Expands Board of Directors with Appointment of Alka Batycky, Ph.D.

Retrieved on: 
Tuesday, May 30, 2023
University, GSK, Defecation, Medical Research Council, Research, Audit committee, Alkermes, Patient, School, Pharmacy school, AMAG Pharmaceuticals, Therapy, Medical Research Council (United Kingdom), Pharmaceutical industry, Nursing, Pharmacy, Ulcerative colitis

NEW YORK, May 30, 2023 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP), a clinical-stage biopharmaceutical company developing novel, oral medicines for patients with autoimmune diseases, today announced the appointment of Alka Batycky, Ph.D. to its Board of Directors and Audit Committee.

Key Points: 
  • NEW YORK, May 30, 2023 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP), a clinical-stage biopharmaceutical company developing novel, oral medicines for patients with autoimmune diseases, today announced the appointment of Alka Batycky, Ph.D. to its Board of Directors and Audit Committee.
  • “Dr.
  • Batycky is an accomplished biopharmaceutical executive and an important addition to Landos’ Board,” said Gregory Oakes, President and CEO of Landos.
  • Prior to this, she held executive leadership positions at various biopharmaceutical companies including Ohana Biosciences, Akashi Therapeutics, Warp Drive Bio and AMAG Pharmaceuticals.

Viridian Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Tuesday, May 9, 2023
Spark Therapeutics, ARVO, Medical Affairs Bureau, Partnership, D, Horizon Therapeutics, Chief commercial officer, CMC, Coronavirus Scientific Advisory Board, MBA, Research, CCO, CDO, Protein, Graves' ophthalmopathy, Chemistry, Injection, AMAG, Patient, Investment, Takeda Oncology, Annual general meeting, Sanofi, Webcast, Alexion, Growth, AMAG Pharmaceuticals, FDA, IND, Therapy, Food, Horizon, Safety, TED, Management, Pharmaceutical industry, Vaccine, Genzyme, Takeda, Clearside, Ophthalmology, Viridian

WALTHAM, Mass., May 09, 2023 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced financial results and provided a corporate update for the first quarter ended March 31, 2023.

Key Points: 
  • “We began 2023 building significant momentum with the VRDN-001 low dose data update in patients with active TED.
  • Viridian plans to file the investigational new drug application (IND) for VRDN-003 with the US Food and Drug Administration (FDA) in the second quarter of 2023.
  • The Company expects topline results from Phase 1 trials evaluating VRDN-003 and VRDN-001 SC in healthy volunteers in the fourth quarter of 2023.
  • The Company will host a webcast and conference call to discuss its first quarter 2023 financial results and provide a corporate update today, Tuesday, May 9, 2023 at 4:30 p.m.

Viridian Therapeutics Appoints Tony Casciano as Chief Commercial Officer

Retrieved on: 
Wednesday, April 12, 2023
University, Bridgewater State University, Marketing, General Medicine Faculty of RostGMU (Rostov State Medical University), Bridgewater, CCO, Graves' ophthalmopathy, AMAG, Patient, AMAG Pharmaceuticals, Therapy, TED, Pharmaceutical industry, Management, Viridian

WALTHAM, Mass., April 12, 2023 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced the appointment of Tony Casciano to the role of Chief Commercial Officer (CCO).

Key Points: 
  • WALTHAM, Mass., April 12, 2023 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced the appointment of Tony Casciano to the role of Chief Commercial Officer (CCO).
  • The Company also announced that Chief Operating Officer (COO) Carrie Melvin is no longer with the organization.
  • Mr. Casciano, who most recently served as Chief Executive Officer (CEO) and member of the board of directors of Teal Bio, brings to Viridian more than two decades of sales, marketing, and commercial leadership experience in the biopharma industry.
  • “Tony’s arrival marks an important milestone in Viridian’s growth and maturation,” said Scott Myers, President and CEO of Viridian.

Viridian Appoints Scott Myers as President and Chief Executive Officer

Retrieved on: 
Monday, February 6, 2023
Employment, AMAG Pharmaceuticals, AMAG, Acquisition, Master of Business Administration, DOV Pharmaceutical, Business administration, UCB, Sale, Scott Myers, Patient, University of Chicago Booth School of Business, Seagen, Business, Growth, Trillium, Johnson & Johnson, University, Therapy, Pfizer, Management, Fine chemical, Pharmaceutical industry, Northwestern University, Viridian, Biology, TED

Mr. Myers has more than 30 years of biopharmaceutical and medical technology experience, and has held global executive leadership and director roles at numerous commercial- and development-stage biopharmaceutical companies.

Key Points: 
  • Mr. Myers has more than 30 years of biopharmaceutical and medical technology experience, and has held global executive leadership and director roles at numerous commercial- and development-stage biopharmaceutical companies.
  • “Scott brings to Viridian extensive late-stage clinical development, global commercial, and executive leadership experience with a proven track record of creating value.
  • His appointment puts Viridian in a position to build upon the Company’s strong foundation to achieve our shared vision of becoming a fully-integrated biopharmaceutical company.
  • Viridian also announced the grant of an inducement award to Mr. Myers as an inducement material to Mr. Myers’ employment pursuant to Rule 5635(c)(4) of the Nasdaq Listing Rules.

Catalent Appoints Ricardo Zayas as North American Biologics Operations Leader

Retrieved on: 
Tuesday, January 17, 2023
Medical Supplies, Health, Research, Pharmaceutical, Science, Biotechnology, Bristol Myers Squibb, AMAG Pharmaceuticals, API, Avon Products, CTLT, Senior, NYSE, Sterling Drug, Warner–Lambert, Patient, Engineering, Kansas State University, Product strategy, Schering-Plough, Multimedia, Supply chain, Management, Pharmaceutical industry, Catalent, Pfizer, Operation

Catalent, Inc. (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, today announced the appointment of Ricardo Zayas as Senior Vice President, Operations, Biologics North America.

Key Points: 
  • Catalent, Inc. (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, today announced the appointment of Ricardo Zayas as Senior Vice President, Operations, Biologics North America.
  • Mr. Zayas will be responsible for all of the company’s North American biologics operations, including its centers of excellence for drug product fill/finish in Bloomington, Indiana, and gene therapy manufacturing in Harmans, Maryland.
  • He will serve on the Executive Leadership Team, reporting directly to Catalent’s President & Chief Executive Officer, Alessandro Maselli.
  • View the full release here: https://www.businesswire.com/news/home/20230117005260/en/
    Ricardo Zayas, who joins Catalent as Senior Vice President, Operations, Biologics North America.

CHARM Therapeutics Strengthens Leadership Team with Key Appointments to Support Drug Discovery and Development Capability

Retrieved on: 
Wednesday, January 4, 2023
Biomedicine, Hoffmann-La Roche, Khosla Ventures, Stanford University, D, Machine learning, Roivant Sciences, Agios Pharmaceuticals, Pfizer, Doctor of Philosophy, Drug discovery, Head, Research, General Catalyst, Publication, Biology, Master of Science, Medicine, The Tumor, University of Minnesota College of Food, Agricultural and Natural Resource Sciences, Intelligence, AMAG Pharmaceuticals, ARIAD Pharmaceuticals, 3D, Therapy, Drug development, Vertex, Deep learning, GSK, Toxicology, University, Family, Cancer Research UK, Cell, Senior, Weill Cornell Graduate School of Medical Sciences, Pharmacokinetics, Merck & Co., MBA, Data management, Moscow State University, Immersion, DPU, Medical device, Pharmaceutical industry, Management, Crystallography, Science, Health care, Economics, Pharmacology, AI, Nature

LONDON – 4 January 2023 -- CHARM Therapeutics (“CHARM”, “The Company”), a 3D deep-learning research Company discovering and developing transformational medicines, today announces the expansion of its leadership team with a series of key appointments to strengthen its drug discovery and development, as well as operational management capabilities.

Key Points: 
  • Enhanced leadership team brings strong AI and drug discovery expertise and experience, reinforcing CHARM Therapeutics’ existing R&D capabilities
    LONDON – 4 January 2023 -- CHARM Therapeutics (“CHARM”, “The Company”), a 3D deep-learning research Company discovering and developing transformational medicines, today announces the expansion of its leadership team with a series of key appointments to strengthen its drug discovery and development, as well as operational management capabilities.
  • These appointments will support CHARM as it builds out of its research and development function to advance discoveries driven by its proprietary 3D deep-learning engine towards development.
  • CHARM Therapeutics raised $50 million in a Series A financing round announced in 2022, led by F-Prime Capital and OrbiMed, with General Catalyst and Khosla Ventures.
  • Gary D. Glick Ph.D., Executive Chair of CHARM Therapeutics, commented: “The exceptional people joining CHARM bring the perfect combination of skills, from immersion in AI, oncology and translational research to long experience in organizational leadership.